SWOG clinical trial number
CTSU/R0415

A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer

Closed
Phase
Abbreviated Title
Local Prostate
Activated
07/01/2006
Closed
11/06/2009
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Radiation Therapy

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2019

Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415

M Thor;J Deasy;R Paulus;W Lee;M Amin;D Bruner;D Low;A Shah;S Malone;J Michalski;I Dayes;S Seaward;E Gore;M Albert;T Pisansky;S Faria;Y Chen;B Koontz;G Swanson;S Pugh;H Sandler Radiotherapy and Oncology Jun;135:19-24; doi: 10.1016/j.radonc.2019.02.014. Epub 2019 Mar 5.

PMid: PMID31015166 | PMC number: PMC6582638

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase